Compare GE Vernova Inc (GEV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

GE Vernova (GEV) trades at $1,004.04, up 0.73% with strong technical momentum and bullish moving averages. The company shows impressive fundamentals with 23% net income margin and 91% ROE, though valuation multiples appear elevated. Recent Q2 earnings missed expectations, but analyst consensus remains strongly bullish with a $1,270 price target. The company secured the first US construction permit for its BWRX-300 small modular reactor, positioning it for AI-driven power demand growth.

GEV offers exposure to the accelerating AI power infrastructure theme with a $176 billion backlog, but faces execution risks in its wind segment and valuation concerns. The stock's 45% YTD gain reflects optimism about nuclear energy adoption, though profitability consistency remains key for further upside. Near-term resistance sits at $1,010-$1,017 with support at $990-$984.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.